Free Trial

Inhibrx (INBX) Earnings Date, Estimates & Call Transcripts

Inhibrx logo
$14.09 -0.46 (-3.16%)
(As of 04:27 PM ET)
Get Inhibrx Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibrx and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

INBX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

INBX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Inhibrx Analyst EPS Estimates

Current Year EPS Consensus Estimate:$104.88 EPS
Next Year EPS Consensus Estimate: ($12.08) EPS

Inhibrx Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/13/2024Q2 2024-$3.60$125.48+$129.08$125.48-$0.10M
2/28/2024Q4 2023-$1.07-$1.73 -$0.66-$1.73$0.10M$1.63M
11/9/2023Q3 2023-$1.01-$1.10 -$0.09-$1.10-$0.12M
8/7/2023Q2 2023-$1.02-$1.08 -$0.06-$1.08-$0.03M
5/8/2023Q1 2023-$0.84-$1.12 -$0.28-$1.12$0.30M$0.02M
3/6/2023Q4 2022-$0.80-$0.95 -$0.15-$0.95$0.30M$0.27M

Inhibrx Earnings - Frequently Asked Questions

Inhibrx (NASDAQ:INBX) has a recorded annual revenue of $1.57 million.

Inhibrx (NASDAQ:INBX) has a recorded net income of -$154.96 million. INBX has generated $0.00 earnings per share over the last four quarters.

Inhibrx's earnings are expected to decrease from $104.88 per share to ($12.08) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:INBX) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners